Toll Free: 1-888-928-9744
Published: Jan, 2015 | Pages:
38 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)
Chlamydia Trachomatis Infections - Pipeline Review, H1 2015 Summary Global Markets Direct's, 'Chlamydia Trachomatis Infections - Pipeline Review, H1 2015', provides an overview of the Chlamydia Trachomatis Infections's therapeutic pipeline. This report provides comprehensive information on the therapeutic development for Chlamydia Trachomatis Infections, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Chlamydia Trachomatis Infections and special features on late-stage and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - The report provides a snapshot of the global therapeutic landscape of Chlamydia Trachomatis Infections - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Chlamydia Trachomatis Infections and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Chlamydia Trachomatis Infections products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Chlamydia Trachomatis Infections pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Chlamydia Trachomatis Infections - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Chlamydia Trachomatis Infections pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents Table of Contents 2 List of Tables 4 List of Figures 4 Introduction 5 Global Markets Direct Report Coverage 5 Chlamydia Trachomatis Infections Overview 6 Therapeutics Development 7 Pipeline Products for Chlamydia Trachomatis Infections - Overview 7 Pipeline Products for Chlamydia Trachomatis Infections - Comparative Analysis 8 Chlamydia Trachomatis Infections - Therapeutics under Development by Companies 9 Chlamydia Trachomatis Infections - Therapeutics under Investigation by Universities/Institutes 10 Chlamydia Trachomatis Infections - Pipeline Products Glance 11 Clinical Stage Products 11 Early Stage Products 12 Unknown Stage Products 13 Chlamydia Trachomatis Infections - Products under Development by Companies 14 Chlamydia Trachomatis Infections - Products under Investigation by Universities/Institutes 15 Chlamydia Trachomatis Infections - Companies Involved in Therapeutics Development 16 ActivBiotics Pharma, LLC 16 Big DNA Ltd. 17 Foamix Pharmaceuticals Ltd. 18 Prokarium Ltd. 19 Chlamydia Trachomatis Infections - Therapeutics Assessment 20 Assessment by Monotherapy Products 20 Assessment by Target 21 Assessment by Mechanism of Action 23 Assessment by Route of Administration 25 Assessment by Molecule Type 27 Drug Profiles 29 BDNA-003 - Drug Profile 29 Product Description 29 Mechanism of Action 29 R&D Progress 29 chlamydia trachomatis vaccine - Drug Profile 30 Product Description 30 Mechanism of Action 30 R&D Progress 30 chlamydia vaccine - Drug Profile 31 Product Description 31 Mechanism of Action 31 R&D Progress 31 minocycline Gel - Drug Profile 32 Product Description 32 Mechanism of Action 32 R&D Progress 32 rifalazil - Drug Profile 33 Product Description 33 Mechanism of Action 33 R&D Progress 33 Chlamydia Trachomatis Infections - Recent Pipeline Updates 35 Chlamydia Trachomatis Infections - Product Development Milestones 36 Featured News & Press Releases 36 Apr 26, 2010: Foamix is granted a fourth U.S. patent for OilGel, directed to pharmaceutical compositions and their dermatological, gynecological and ophthalmic applications 36 Appendix 37 Methodology 37 Coverage 37 Secondary Research 37 Primary Research 37 Expert Panel Validation 37 Contact Us 38 Disclaimer 38
List of Tables Number of Products under Development for Chlamydia Trachomatis Infections, H1 2015 7 Number of Products under Development for Chlamydia Trachomatis Infections - Comparative Analysis, H1 2015 8 Number of Products under Development by Companies, H1 2015 9 Number of Products under Investigation by Universities/Institutes, H1 2015 10 Comparative Analysis by Clinical Stage Development, H1 2015 11 Comparative Analysis by Early Stage Development, H1 2015 12 Comparative Analysis by Unknown Stage Development, H1 2015 13 Products under Development by Companies, H1 2015 14 Products under Investigation by Universities/Institutes, H1 2015 15 Chlamydia Trachomatis Infections - Pipeline by ActivBiotics Pharma, LLC, H1 2015 16 Chlamydia Trachomatis Infections - Pipeline by Big DNA Ltd., H1 2015 17 Chlamydia Trachomatis Infections - Pipeline by Foamix Pharmaceuticals Ltd., H1 2015 18 Chlamydia Trachomatis Infections - Pipeline by Prokarium Ltd., H1 2015 19 Assessment by Monotherapy Products, H1 2015 20 Number of Products by Stage and Target, H1 2015 22 Number of Products by Stage and Mechanism of Action, H1 2015 24 Number of Products by Stage and Route of Administration, H1 2015 26 Number of Products by Stage and Molecule Type, H1 2015 28 Chlamydia Trachomatis Infections Therapeutics - Recent Pipeline Updates, H1 2015 35
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.